Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]
Awaiting development
Reference number: GID-TA11748
Expected publication date: TBC
To appraise the clinical and cost effectiveness of Pirtobrutinib + Venetoclax + Rituximab within its marketing authorisation for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma